reports
- GlobalData Healthcare Department
Vitae Pharmaceuticals Inc (VTAE) - Pharmaceuticals & Healthcare - Deal...
Summary Vitae Pharmaceuticals Inc (Vitae Pharmaceuticals) is a biopharmaceutical company that offers pharmaceutical products. The company discovers and develops and small molecule drugs for diseases with significant unmet medical needs. Its products pipeline includes VTP-34072, BI 1147560, VTP-43742, VTP-38543 and VTP-38443. Vitae Pharmaceuticals’ products address therapeutic areas such as diabetes, Alzheimer’s disease, atopic dermatitis, autoimmune disorders, and acute coronary syndrome. T...
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Propo...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE) (“Vitae” or the “Company”) relating to the proposed buyout of Vitae by Allergan plc. Under the terms of the agreement, Vitae shareholders are anticipated to receive $21.00 in cash for each share of Vitae common stock held. The firm’s inves...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Re...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Vitae Pharmaceuticals, Inc. (“Vitae Pharmaceuticals”) (NASDAQ: VTAE) stock prior to September 14, 2016. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Vitae Pharmaceuticals to Allergan plc for $21.00 per share. The transaction has a total approximate value of $639 million. To learn more about the action and yo...
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Pr...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE) (“Vitae” or the “Company”) relating to the proposed buyout of Vitae by Allergan plc. Under the terms of the agreement, Vitae shareholders are anticipated to receive $21.00 in cash for each share of Vitae common stock held. The firm’s inves...
VITAE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Vitae Pharmaceuticals, Inc. (NASDAQ GM: VTAE)? Did you purchase any of your shares prior to September 14, 2016? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Vitae Pharmaceuticals, Inc. (“Vitae” or the “Company”) (NAS...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.